| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_TMEM56_0001200 | Exon-Exon | chr1:95609447-95659920 | chr1:95143891-95194364 | 151 nt | 0.4371 |
| hsa_TMEM56_0001400 | Intron-Intron | chr1:95640000-95640432 | chr1:95174444-95174876 | 433 nt | 0.3995 |
| hsa_TMEM56_0001500 | Intron-Intron | chr1:95650769-95651532 | chr1:95185213-95185976 | 764 nt | 0.3887 |
| hsa_TMEM56_0001600 | Intron-Intron | chr1:95651149-95652070 | chr1:95185593-95186514 | 922 nt | 0.3915 |
| hsa_TMEM56_0001700 | Intron-Intron | chr1:95651946-95652149 | chr1:95186390-95186593 | 204 nt | 0.4216 |
| hsa_TMEM56_0001900 | Exon-Exon | chr1:95662369-95662516 | chr1:95196813-95196960 | 148 nt | 0.3041 |
A study in humans demonstrated that the circTMEM56 is significantly lower in the serum of patients with hypertrophic cardiomyopathy (HCM) compared to healthy controls, showing a negative correlation with the severity of left ventricular obstruction in obstructive HCM and achieving an area under the curve (AUC) of 0.738 for diagnostic potential [Tian et al. DOI:10.3390/molecules26041155].